Drugs / ISIS 113715
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00365781 | Aug → Sep 2006 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00327626 | May 2006 → Feb 2007 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00330200 | Nov 2005 → Mar 2007 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00330330 | Feb 2003 → Aug 2006 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00455598 Comparator | Feb 2007 → Mar 2009 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2010-06-29 | Ionis Pharmaceuticals | Results Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions ionis.com ↗
The most common adverse event was mild injection site reactions. |
| 2009-10-21 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 113715 in Patients With Type 2 Diabetes ionis.com ↗
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. |
| 2006-08-03 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Financial Results And Highlights For Second Quarter Of 2006 ionis.com ↗
Isis Reports Positive Phase 2 Data on ISIS 113715 for the Treatment of Type 2 Diabetes |
| 2006-06-13 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Positive Phase 2 Data: ISIS 113715 Improves Glucose Control in Patients With Type 2 Diabetes ionis.com ↗
An intent-to-treat analysis of all patients enrolled in the trial treated with 200 mg/wk for three months showed statistically significant improvement in multiple measures of glucose control. |
| 2005-06-14 | Ionis Pharmaceuticals | Results ISIS 113715 Improves Glucose Control in Patients With Type 2 Diabetes ionis.com ↗
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that ISIS 113715 reduced HbA1C and plasma glucose after six weeks of dosing. |
| 2003-10-27 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Updates Positive Clinical Data on Multiple Antisense Drugs ionis.com ↗
results from a Phase 1 study involving ISIS 113715 for type 2 diabetes were reported at the Nucleic Acid World Summit in September. |
| 2003-09-16 | Ionis Pharmaceuticals | Results Second-Generation Type 2 Diabetes Antisense Drug Improves Glucose Tolerance Tests in Normal Volunteers in Phase 1 Study ionis.com ↗
All volunteers that received ISIS 113715 (6 of 6) experienced the desired effect, increased insulin sensitivity. |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 113715 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00330200 ↗ |
| Action | Inhibit | “Inhibitor of Protein Tyrosine Phosphatase 1B” NCT00365781 ↗ |
| Modality | Antisense oligonucleotide | “Antisense Oligonucleotide Inhibitor” NCT00365781 ↗ |
| Route | Subcutaneous | “ISIS 113715 subcutaneous doses” NCT00327626 ↗ |